Why AstraZeneca May Dominate the European Vaccine Market

Adria Cimino, The Motley Fool
·2-min read

Demand in the U.S. might be limited, since President Joe Biden recently bought enough vaccine doses from Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) to vaccinate nearly all Americans. In this Motley Fool Live video recorded on Feb. 26, 2021, healthcare and cannabis bureau chief Corinne Cardina and Fool.com contributor Adria Cimino discuss opportunity in Europe and why AstraZeneca might have an advantage.